Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is expected to see a turning point in its domestic business in 2025 due to the anticipated recovery in local special bonds and monthly bidding for various medical devices, despite short-term impacts from tight local finances and delays in regular tenders [1] - The international market is projected to grow significantly, driven by the company's continued penetration into high-end customer segments and balanced revenue distribution across major global regions, particularly in developing countries and Europe [1] - The company is expected to maintain steady long-term growth, supported by the global medical infrastructure wave and expansion into high-end markets [5] Business Segmentation and Highlights - **Life Information and Support Segment**: Revenue decreased by 11.1% in 2024, with minimally invasive surgery business growing over 30%. Internationally, this segment achieved double-digit growth [2] - **In Vitro Diagnostics Segment**: Revenue grew by 10.8% in 2024, surpassing the Life Information and Support segment for the first time. Internationally, this segment saw growth exceeding 30% [3] - **Medical Imaging Segment**: Revenue increased by 6.6% in 2024, with international business growing over 15%. The high-end ultrasound system Resona A20 generated over 400 million yuan in its first year [3] Profitability Analysis - The company's gross margin for 2024 was 63.1%, a decrease of 3.0 percentage points year-on-year, while the net profit margin was 32.0%, down 1.2 percentage points [4] - Operating cash flow for 2024 was 12.43 billion yuan, a year-on-year increase of 12.4%, representing 102.8% of net operating income [4] - Profitability is expected to improve slightly from 2025 to 2027, driven by an increase in high-end product sales and stable operating expense ratios [4] Financial Forecast and Valuation - The company is projected to maintain stable growth from 2025 to 2027, with expected revenues of 40.33 billion yuan in 2025, 45.76 billion yuan in 2026, and 52.50 billion yuan in 2027, reflecting growth rates of 9.82%, 13.46%, and 14.72% respectively [12] - The estimated earnings per share (EPS) for 2025 is 10.61 yuan, with a price-to-earnings (P/E) ratio of 21.86 [10][12]

数据来源：聚源 -36% -24% -12% 0% 12% 24% 2024-05 2024-09 2025-01 迈瑞医疗 沪深300 相关研究报告 医药生物/医疗器械 迈瑞医疗（300760.SZ） 国内市场蓄势待发，海外业务高歌猛进 2025 年 05 月 22 日 投资评级：买入（维持） | 日期 | 2025/5/21 | | --- | --- | | 当前股价(元) | 226.67 | | 一年最高最低(元) | 351.60/206.80 | | 总市值(亿元) | 2,748.24 | | 流通市值(亿元) | 2,748.19 | | 总股本(亿股) | 12.12 | | 流通股本(亿股) | 12.12 | | 近 3 个月换手率(%) | 29.21 | 股价走势图 《高耗+设备整体解决方案落地与数 智化发展可期—公司信息更新报告》 -2024.6.18 Yoy ——公司信息更新报告 | 余汝意（分析师） | 石启正（联系人） | | --- | --- | | yuruyi@kysec.cn | shiqizheng@kysec.cn | | 证书编号：S079052307000 ...

三大主业合力增长 业绩稳健、优质分红企业价值凸显 4月28日，迈瑞医疗（300760.SZ）披露2024年年度报告。报告期内，公司实现营业收入367.26亿元，同 比增长5.14%；实现归母净利润116.68亿元，同比增长0.74%。在行业普遍低迷的环境下，公司依然保持 了自2018年A股上市以来连续7年营收、归母净利润双增长。 同时，迈瑞医疗披露了2024年度利润分配预案，计划以12.12亿总股本为基数，向全体股东每10股派发 现金股利人民币5.60元（含税），合计派发6.79亿元（含税）。加上公司2024年已经实施的中期利润分 配和第二次中期利润分配合计派发的69.23亿元（含税），2024年度，公司累计现金分红总额将达到 76.02亿元，现金分红比例高达65.15%。 此外，公司还计划推出2025年第一次中期利润分配预案，预计派发17.10亿元（含税），并请求股东大 会授权董事会根据公司实际情况制定2025年其他中期分红方案。迈瑞医疗在保持业绩稳健增长的前提 下，持续推动一年多次与投资者共享发展成果。 连续七年分红总额超340亿 制定未来三年股东回报计划 年报显示，自迈瑞2018年上市以来便未进行过再融 ...